Torrent Pharma, Eli Lilly ink pact to boost Baricitinib production in India
Ahmedabad: Following in the footsteps of Sun Pharma, Cipla, and Lupin in signing a voluntary licencing agreement with Eli Lilly to accelerate the production of Baricitinib for the treatment of COVID-19 patients in India, now Torrent Pharmaceuticals has signed a royalty free, non-exclusive voluntary licencing agreement with Eli Lilly to boost the production of Baricitinib.
Under the agreement, Lilly has provided the license to manufacture and distribute baricitinib to Torrent for India along with Lilly's other license partners.
The agreement will help ensure wider reach and access to patients in India and further adds to Torrent Pharma's effort in helping patients affected by the pandemic. Baricitinib has been approved by the Central Drug Standard Control Organisation (CDSCO), India for restricted emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.
Commenting on the agreement, Aman Mehta, Chief Marketing Officer for Torrent said, "We are pleased to partner and work closely with Lilly to bring this treatment to market. This partnership further strengthens our efforts to help the nation fight the pandemic and provide quality treatment to patients. Torrent Group stands firmly committed to support the nation during this time of crisis."
Read also: Eli Lilly ink licensing pact with Sun Pharma, Cipla, Lupin to expedite COVID drug Baricitinib
Next Story